TOP > 外国特許検索 > PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICINAL COMPOSITION FOR PREVENTING AND/OR TREATING CATARACT, USE OF PPAR ACTIVATOR FOR PRODUCING SAME, AND EYEDROPS

PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICINAL COMPOSITION FOR PREVENTING AND/OR TREATING CATARACT, USE OF PPAR ACTIVATOR FOR PRODUCING SAME, AND EYEDROPS NEW コモンズ

外国特許コード F190009927
整理番号 (FU773)
掲載日 2019年10月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP048211
国際公開番号 WO 2019131897
国際出願日 平成30年12月27日(2018.12.27)
国際公開日 令和元年7月4日(2019.7.4)
優先権データ
  • 特願2017-254614 (2017.12.28) JP
発明の名称 (英語) PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICINAL COMPOSITION FOR PREVENTING AND/OR TREATING CATARACT, USE OF PPAR ACTIVATOR FOR PRODUCING SAME, AND EYEDROPS NEW コモンズ
発明の概要(英語) Provided are: a prophylactic agent and a therapeutic agent for cataract, said agents having a different function mechanism from conventional agents; and use of a PPAR activator for producing the same. Use is made of a prophylactic agent and/or a therapeutic agent for cataract, said agents comprising a PPAR activator as an active ingredient.
従来技術、競合技術の概要(英語) BACKGROUND ART
A cataract, the quartz body (e.g., opaque) opacity by, a disease reduction in visual acuity. Who is suffering from cataract, in general, the quartz body, nuclear, cortical, or, such as turbid occurs after the bladder.
As a type of cataract, cataract aging, and, such as cataracts and diabetic. Aging a cataract, the user is suffering from cataract in the greatest number. In the case of a cataract age, age-related increase in the number of patients with, about 66-85% of the twenties Japanese 60, 70 to about 84-97% of the Japanese twenties, the age of 80 from age of 100% suffering from cataract in Japanese that is reported. On the other hand, in the case of a cataract diabetes, a number of affected individuals 60 years old or younger, cataract is diabetes, the youth may also develop a disease.
As a method for the treatment of cataracts, surgery, and, the administration of prophylactic or therapeutic agent, can be cited. The prophylactic and therapeutic agent as an example, glutathione, it is, can be exemplified an agent comprising pirenoxine (see Non-Patent Document 1 and 2).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • UNIVERSITY OF FUKUI
  • SANTEN PHARMACEUTICAL CO., LTD.
  • 発明者(英語)
  • OKI, Masaya
  • KANADA, Fumito
  • KAMATA, Kazuma
  • TAKAMURA, Yoshihiro
  • MIYAKE, Seiji
  • INATANI, Masaru
  • UCHIDA, Hiroyuki
  • NOGATA, Miho
  • KATO, Masatomo
  • FUJISAWA, Koushi
  • TAKAOKA, Shinji
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close